Table 1.
Characteristics of HCC patients
| Variables | Median (range)/Mean±SD/N (%) |
|---|---|
| Gender(male/female) | 298(82.8%)/62(17.2%) |
| Age,years | 59.2±10.9 |
| HBV(yes/no) | 311(86.4%)/49(13.6%) |
| Anti-HBV(yes/no) | 129(35.8%)/231(64.2%) |
| Family history of HCC | 16(4.4%)/344(95.6%) |
| Hypertension(yes/no) | 101(28.1%)/259(71.9%) |
| Diabetes(yes/no) | 47(13.1%)/313(86.9%) |
| ALT, U/L (≤50/>50) | 287(79.7%)/73(20.3%) |
| ALP, U/L (≤125/>125) | 286(79.4%)/74(20.6%) |
| GGT, U/L (≤60/>60) | 204(56.7%)/156(43.3%) |
| PT, seconds (≤13/>13) | 303(84.2%)/57(15.8%) |
| ALBI(≤-2.60/ -2.60 to -1.39/>-1.39) | 236(65.6%)/120(33.3%)/4(1.1%) |
| DB, umol/l (≤8/>8) | 297(82.5%)/63(17.5%) |
| INR(≤1/>1) | 85(23.6%)/275(76.4%) |
| AFP,ng/mL (≤20/20 to 400/>400) | 167(46.4%)/96(26.7%)/97(26.9%) |
| PNI | 48.9(26.5,73.3) |
| APRI | 0.22(0.04,4.58) |
| ALRI | 21.70(5.67,514.62) |
| ANRI | 10.72(1.51,209.06) |
| SII | 296.59(50.80,7846.67) |
| NLR | 2.00(0.40,73.33) |
| PLR | 102.18(30.91,500.00) |
| MLR | 0.29(0.12,5.17) |
| SIRI | 0.85(0.21,75.43) |
| Pathological differentiation(well/moderate/poor) | 167(46.4%)/96(26.7%)/97(26.9%) |
| MVI(yes/no) | 180(50%)/180(50%) |
| Cirrhosis(yes/no) | 173(48.1%)/187(51.9%) |
| Number of tumours(solitary/multiple) | 290(80.6%)/70(19.4%) |
| Tumour diameter, cm | 4.98±3.07 |
| Tumour capsule(yes/no) | 299(83.1%)/61(16.9%) |
| PVTT(yes/no) | 30(8.3%)/330(91.7%) |
| Child-Pugh grade (A/B) | 354(98.3%)/6(1.7%) |
| AJCC T stage (I - II /III - IV) | 280(77.8%)/80(22.2%) |
Abbreviations: HBV Hepatitis B Virus, ALT alanine aminotransferase, ALPalkaline phosphatase, GGT γ-glutamyl transpeptidase, PT prothrombin time, DB direct bilirubin, INR international normalized ratio, AFP alpha-fetoprotein, MVI microvascular invasion, PVTT portal vein tumour thrombosis